Business
Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects
Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / June 1, 2021 / Halberd Corporation (OTC PINK:HALB) announced the filing of a U. S. joint provisional patent application titled, "Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2." The innovation is a result of Halberd's Sponsored Research conducted at Arizona State University (ASU). The provisional patent application covers technology developed to facilitate conjugation of metallic nanoparticles with antibodies against various bacteria and SARS-CoV-2, for elimination via radio waves. Additionally, the patent discloses the use of such a conjugated moiety as a means of detecting the presence and level of the SARS-CoV-2 viral load in a patient.Dr. Mitchell S. Felder, Halberd Corporation's Chief Technical Officer and co-inventor of the technology, stated, "The conjugation of a metallic nanoparticle with either a bacterial or viral antibody which produces a stable moiety is not an obvious procedure. The researchers at ASU did a phenomenal job in a short period of time, allowing our extracorporeal disease eradication testing to go forward as planned. A side benefit of this work is that the moiety is potentially capable of detecting not only the presence of SARS-CoV-2, or a bacterial infection - but also of detecting the level of disease load in the patient."William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Although our research was prompted by and focused on Covid-19, the technology developed has demonstrated far reaching benefit towards the detection and elimination of other viruses and bacterial infections. Through Halberd's patented extracorporeal process of exposing the infected blood or cerebral spinal fluid to tuned radio waves or laser emissive energy, we believe we will be able to successfully treat a wide range of illnesses and diseases."To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.(http://halberdcorporation.com/contact-us/)For more information please contact:William A. [email protected]@halberdcorporation.comwww.halberdcorporation.comTwitter:@HalberdCAbout Halberd Corporation.Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and...